RecruitingNCT04087473

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Plasma Molecular Profiling in ALK Inhibitor Resistant Non-Small Cell Lung Cancer

Sponsor

National Cancer Centre, Singapore

Enrollment

50 participants

Start Date

Aug 23, 2019

Study Type

OBSERVATIONAL

Conditions

Non-small Cell Lung Cancer ALK-Positive Lung Cancer

Summary

The investigators plan to understand a comprehensive molecular profiling via the plasma, with the primary aim of using this form on analysis to guide subsequent treatment selection. This study will provide a better understanding of ALK resistance in the treatment of Asian lung cancers and allow for improved clinical outcomes by 'matching' the secondary mutations to an ALK inhibitor which would allow for the greatest coverage ultimately leading to lasting duration of response.

Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood samples from patients with advanced lung cancer that has a specific genetic change (ALK rearrangement) and has stopped responding to targeted treatments called ALK inhibitors. Researchers will analyze these blood samples to understand why the cancer stopped responding and to look for new treatment targets. **You may be eligible if...** - You are 21 or older - You have advanced ALK-positive lung adenocarcinoma (a type of non-small cell lung cancer) - Your cancer has progressed after 1–2 ALK inhibitor drugs, including at least one second-generation drug (such as alectinib, ceritinib, brigatinib, or ensartinib) - You are in adequate health and have reasonable organ function **You may NOT be eligible if...** - You have received more than 2 ALK inhibitor drugs - You have brain metastases that are causing symptoms or need active treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.